Lucy Gilbert, MD, on Overall Survival by Prior Taxane Use in the Phase III ROSELLA Trial
ASCO 2026
Lucy Gilbert, MD, of McGill University Health Centre, discusses subgroup analyses from the ROSELLA study. Relacorilant plus nab-paclitaxel demonstrated a statistically and clinically significant overall survival benefit in patients with platinum-resistant ovarian cancer compared to a weekly taxane; subgroup analyses for overall survival showed a consistent benefit favoring the addition of relacorilant to nab-paclitaxel irrespective of prior taxane use (Abstract 5503).
The ASCO Post Staff
Shailender Bhatia, MD, of the University of Washington and Fred Hutchinson Cancer Center, presents data from the phase III ADAM trial, a multicenter, randomized, double-blinded, placebo-controlled study of the anti–PD-L1 antibody avelumab in patients with Merkel cell carcinoma and lymph node metastases (Abstract LBA9504).
The ASCO Post Staff
Angimar Uriepero-Palma, MD, of Jefferson Einstein Philadelphia Hospital, discusses a study that showed use of sodium-glucose cotransporter 2 (SGLT2) inhibitors was associated with longer 3-year overall survival and a lower risk of cytopenias and infections among diabetic patients with chronic lymphocytic leukemia (CLL) receiving Bruton’s tyrosine kinase inhibitors (Abstract 7051).
Rami Manochakian, MD, FASCO, of Mayo Clinic Florida, summarizes an educational session at ASCO that reviewed the state of the field of small cell lung cancer (SCLC) treatment. After decades of limited treatment progress, advances are being seen in immunotherapies, radiation therapy, bispecific T-cell engagers, antibody-drug conjugates, and radionuclide therapies.
The ASCO Post Staff
Yelena Y. Janjigian, MD, FASCO, of Memorial Sloan Kettering Cancer Center, discusses safety results for DESTINY-Gastric03 Part 2 (arms D and F) and Part 4. The trial evaluated first-line fam-trastuzumab deruxtecan-nxki–based regimens in advanced HER2-expressing gastric cancer, gastroesophageal adenocarcinoma, and esophageal carcinoma (Abstract 4002).
The ASCO Post Staff
Yashasvini Sampathkumar, MD, of Memorial Sloan Kettering Cancer Center, presents data on Talking to Employers and Medical Staff about Work (TEAMWork), an English/Spanish intervention. The English/Spanish intervention, delivered as a booklet or mobile app, was developed to improve work outcomes among women undergoing breast cancer therapy. Dr. Sampathkumar discusses whether the digital vs print format was preferable among this population (Abstract 11060).
